GENE ONLINE|News &
Opinion
Blog

2021-06-29| Asia-PacificCOVID-19

Korea to Begin Production of Sputnik Light COVID-19 Vaccine in September

by Tyler Chen
Share To

South Korea has become a global hub for COVID-19 vaccine manufacturing. After Moderna and Novavax made deals with the Korean government in May to produce their vaccines, the country’s pharma companies said they would start producing the Sputnik Light COVID-19 vaccine as early as September.

 

Aim to Produce 30 Million Doses in 2021

Huons Global, the leading company in its vaccine consortium, said on June 28th that they would start manufacturing sample batches of Sputnik V and Light vaccines in August in order to meet the demand from the Russian Direct Investment Fund (RDIF).

The firm once stated in April that it would make 100 million Sputnik V vaccines a month for export purposes, and now it aims to produce 30 million shots by the end of 2021.

The consortium included Korea’s local pharma firms Huons Global, Prestige BioPharma, Humedix, and Boran Pharma. Huons Global commented in May that it would prioritize the local supply of Sputnik V as soon as it is approved in Korea.

 

Another Deal by RDIF

Huons Global isn’t the only one that had a deal with RDIF. 

On April 15, Korea’s Isu Abxis received a technology transfer of Sputnik V from RDIF to produce the vaccine. It said that the pilot production of the vaccine at the facility in Yongin is expected to begin soon.

Isu Abxis is in a vaccine consortium organized by GL Rapha in February. The consortium also included 8 other domestic companies.

 

Still Under Review in Korea

The efficacy of Sputnik Light is 79.4% with a single shot, and according to the real-world data in Argentina, the vaccine has an efficacy of 78.5 to 83.7% among the elderly. As for conditions for storage, Sputnik Light can be transported at the temperature of 2~8 °C, meaning that it doesn’t require cold-chain infrastructures such as vaccines developed by Pfizer and Moderna.

However, currently, Sputnik V and Sputnik Light are not approved or under review in Korea.

Related Article: Korea’s Incheon Airport to Open a Cool Cargo Center to Store COVID-19 Vaccines

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
AstraZeneca’s COVID-19 Vaccine Finally Wins Full Authorization in the European Union
2022-11-01
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!